BRIAConsumer Cyclical · Apparel RetailBRIA Stock Forecast: BrilliA, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering BrilliA, Inc. hold a median 12-month price target of $2.75 — +96.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
BRIA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores BrilliA, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
BRIA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BRIA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +96.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Aug 2025 | Alliance Global Partners | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRIA appears on the weeks it earns a place.
BRIA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
BrilliA, Inc. (BRIA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 16.8×
- Price / sales
- 0.7×
- Price / book
- 2.9×
- EV / EBITDA
- 112.9×
Cheaper than 44% of US stocks
Cheaper than 77% of US stocks
Cheaper than 36% of US stocks
Cheaper than 2% of US stocks
- Revenue growth (YoY)
- −34.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −0.0%
- Net margin
- −0.0%
Higher than 8% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −0.1%
- Return on assets
- 0.7%
- Dividend yield
- 38.0%
Higher than 44% of US stocks
Higher than 47% of US stocks
Higher than 96% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BRIA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BrilliA, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BRIA stock
What is the BRIA stock price forecast for 2026-2027?
The 1 Wall Street analysts covering BrilliA, Inc. have a median 12-month price target of $2.75, with estimates ranging from $2.75 to $2.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BRIA stock a buy right now?
Of the 1 analysts covering BrilliA, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BrilliA, Inc. 2 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BRIA?
As at 22 Aug 2026, BrilliA, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
Will BRIA stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +96.4% from the last close, and Ticker Nerd's factor model ranks BrilliA, Inc. 2 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BRIA stock forecast for 2030?
No analyst covering BrilliA, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRIA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.75 to $2.75 over the next 12 months.
How has BRIA stock performed over the past year?
BrilliA, Inc. returned -36.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BrilliA, Inc. do?
Brillia Inc. is a thriving organization in the biotechnology sector, focusing on innovative healthcare solutions.
About BrilliA, Inc.
Brillia Inc. is a thriving organization in the biotechnology sector, focusing on innovative healthcare solutions. The primary function of this company revolves around the development and commercialization of advanced therapeutic products aimed at treating diverse medical conditions. Known for their cutting-edge research in regenerative medicine and biologic therapies, Brillia Inc. significantly impacts the pharmaceutical and healthcare industries by introducing new methodologies that enhance patient care and treatment outcomes. Operating at the forefront of medical innovation, Brillia Inc. collaborates with research institutions and clinical experts to ensure the effectiveness and safety of its offerings. This collaborative approach enables the company to navigate regulatory landscapes efficiently and bring groundbreaking treatments to the market promptly. Brillia Inc.'s dedication to improving health outcomes through scientific discovery and its robust pipeline of therapeutic products make it a key player in the biotechnology industry. Its contributions not only advance patient therapy options but also support the broader goals of medical advancement and improved global health standards.
239 employees · Singapore · https://brilliaincorporated.com